Age
Item
subjects aged 12-65.
boolean
C0001779 (UMLS CUI [1])
Idiopathic pulmonary hypertension | Pulmonary arterial hypertension associated with connective tissue disease | Pulmonary arterial hypertension associated with congenital heart disease | Eisenmenger Complex
Item
confirmed idiopathic pulmonary hypertension, connective tissue disease associated pulmonary hypertension, congenital heart disease(with eisenmenger syndrome) associated pulmonary hypertension.
boolean
C0152171 (UMLS CUI [1])
C3697982 (UMLS CUI [2])
C3697119 (UMLS CUI [3])
C0013743 (UMLS CUI [4])
6-Minute Walk Test Meter Quantity
Item
baseline 6-minutes walking distance 150m-550m.
boolean
C0430515 (UMLS CUI [1,1])
C0475209 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
Pulmonary Hypertension WHO classification | Therapy non-responder Calcium Channel Blockers
Item
who pulmonary hypertension function ii-iii with non-responder to calcium channel blockers.
boolean
C0020542 (UMLS CUI [1,1])
C4267671 (UMLS CUI [1,2])
C0919875 (UMLS CUI [2,1])
C0006684 (UMLS CUI [2,2])
Informed Consent
Item
documented written informed consent.
boolean
C0021430 (UMLS CUI [1])
Pulmonary Hypertension Type Other
Item
the other types of pulmonary hypertension.
boolean
C0020542 (UMLS CUI [1,1])
C0332307 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,3])
Informed Consent Refused | Protocol Compliance Limited
Item
subjects who refuse to subscribe written informed consents or can't cooperate with the trial well.
boolean
C0021430 (UMLS CUI [1,1])
C1705116 (UMLS CUI [1,2])
C0525058 (UMLS CUI [2,1])
C0439801 (UMLS CUI [2,2])
Disease Serious Involvement Liver | Disease Serious Involvement Kidney | Disease Serious Involvement Brain | Chronic disease Serious Involvement Liver | Chronic disease Serious Involvement Kidney | Chronic disease Serious Involvement Brain | CYP3A4 Inhibitor Primary disorders | Nitrate Primary disorders
Item
subjects with serious acute or chronic disease involved liver, kidney, and brain or have to use potent cyp3a4-inhibitor or nitrate to treat the underlying diseases.
boolean
C0012634 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C1314939 (UMLS CUI [1,3])
C0023884 (UMLS CUI [1,4])
C0012634 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
C1314939 (UMLS CUI [2,3])
C0022646 (UMLS CUI [2,4])
C0012634 (UMLS CUI [3,1])
C0205404 (UMLS CUI [3,2])
C1314939 (UMLS CUI [3,3])
C0006104 (UMLS CUI [3,4])
C0008679 (UMLS CUI [4,1])
C0205404 (UMLS CUI [4,2])
C1314939 (UMLS CUI [4,3])
C0023884 (UMLS CUI [4,4])
C0008679 (UMLS CUI [5,1])
C0205404 (UMLS CUI [5,2])
C1314939 (UMLS CUI [5,3])
C0022646 (UMLS CUI [5,4])
C0008679 (UMLS CUI [6,1])
C0205404 (UMLS CUI [6,2])
C1314939 (UMLS CUI [6,3])
C0006104 (UMLS CUI [6,4])
C3830624 (UMLS CUI [7,1])
C0277554 (UMLS CUI [7,2])
C0028125 (UMLS CUI [8,1])
C0277554 (UMLS CUI [8,2])
Sildenafil Pulmonary arterial hypertension | sildenafil | tadalafil
Item
subjects who are currently treated with sildenafil for pah or taking sildenafil or tadalafil.
boolean
C0529793 (UMLS CUI [1,1])
C2973725 (UMLS CUI [1,2])
C0529793 (UMLS CUI [2])
C1176316 (UMLS CUI [3])
Package Insert Containing Medical contraindications
Item
other contraindications in package insert.
boolean
C0030174 (UMLS CUI [1,1])
C0332256 (UMLS CUI [1,2])
C1301624 (UMLS CUI [1,3])